2天收获2个IPO，联想之星实现开门红

Core Viewpoint - Lenovo Star's early-stage technology projects are now yielding results, with multiple IPOs on the horizon, marking a concentrated period of success for the firm in the high-tech investment landscape [2][5]. Group 1: Recent IPOs - Lenovo Star celebrated two significant IPOs within two days: Rebio Biotech (6938.HK) and Precision Medical (2675.HK), with Rebio's stock price rising over 23% on its debut, achieving a market capitalization exceeding HKD 11.8 billion [3][5]. - The firm has been a long-term supporter of Rebio Biotech, investing in two rounds since 2015, showcasing its commitment to nurturing early-stage companies [5][11]. Group 2: Investment Strategy and Success - Lenovo Star's success is attributed to its systematic approach to investing in cutting-edge technology and healthcare since 2010, leveraging its ties to the Chinese Academy of Sciences and Lenovo Holdings [6][10]. - The firm emphasizes a long-term investment philosophy, focusing on early-stage biotech companies, which has resulted in a high investment accuracy rate [6][11]. - The company has maintained a comprehensive research coverage of the biopharmaceutical industry, continuously optimizing its investment strategies based on the evolving landscape [11][12]. Group 3: Leadership and Innovation - Rebio Biotech, led by Dr. Liang Zicai, has established itself as a leader in the small nucleic acid drug sector, with a robust R&D platform and innovative delivery technology [9][10]. - Dr. Liang's extensive background in molecular biology and his previous entrepreneurial ventures have positioned Rebio Biotech as a pioneer in the industry [8][9]. Group 4: Future Outlook - Lenovo Star is poised to continue its focus on the biopharmaceutical sector, with an emphasis on high-quality, cost-effective medical solutions, and is adapting its investment strategy to align with emerging trends in the healthcare market [12][13].